 Amid a notable positive session for the major equity indices, Biogen NASDAQ: BIIB really got the party started with a massive 37 boost in the early afternoon session on Wednesday. Biogen disclosed very encouraging results for its final-phase test for lecanemab, an experimental therapeutic for Alzheimers disease. 